Objective:

To discuss the implications of updated FDA labeling on menopausal hormone therapy (MHT) and the need for improved clinical practices, emphasizing the responsibility of clinicians.

Approach:

Key Findings:

• MHT use declined from over 20% to under 5% after the Women’s Health Initiative, highlighting the need for updated practices.
• Updated FDA labeling reflects a favorable benefit-risk profile for MHT when initiated early.
• Gaps exist in menopause education and clinical practice, particularly among non-specialized clinicians, affecting patient access to care.

Interpretation:

The updated FDA guidance provides a chance for clinicians to reassess their practices and improve care for menopausal women, emphasizing the importance of individualized treatment plans.

Limitations:

• Access to MHT varies by insurance coverage, and newer treatment options may face authorization hurdles, impacting patient care.
• Not all clinicians may be equipped or trained to implement menopause symptom screening effectively, which can hinder proper treatment.

Conclusion:

Clinicians are encouraged to integrate menopause symptom assessment and treatment into their practice, supported by continuing education and evidence-based resources.

Sources:

• JAMA Perspective
Source

Based on findings from:

Rethinking Menopause Hormone Therapy

Kerri Miller. MDSpire News, 2026.

https://news.mdspire.com/obgyn/articles/rethinking-menopause-hormone-therapy/

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.